Skip to main content
Download PDF
Download ePub
  • Primary research
  • Open access
  • Published:

A cross-sectional study on metabolic similarities and differences between inpatients with schizophrenia and those with mood disorders

Annals of General Psychiatry volume 19, Article number: 53 (2020) Cite this article

Abstract

Background

One of the main causes of death in psychiatric patients is cardiovascular diseases which are closely related with lifestyle-related diseases. Psychiatric disorders include schizophrenia and mood disorders, whose symptoms and treatment medicines are different, suggesting that they might have different metabolic disorders. Thus, we studied the differences of lifestyle-related diseases between schizophrenia and mood disorders in Japan.

Methods

This cross-sectional study was performed from 2015 to 2017. Study participants were 189 Japanese hospitalized patients (144 schizophrenia group, 45 mood disorders group) in the department of psychiatry at Kohnodai hospital. We examined physical disorders, metabolic status of glucose and lipid, estimated glomerular filtration rate (eGFR) and brain magnetic resonance imaging. We compared these data between schizophrenia and mood disorders groups using analysis of covariance or logistic regression analysis. In comparisons between inpatients with schizophrenia or mood disorders group and the standard, we quoted ‘The National Health and Nutrition Survey in Japan 2015’ by Ministry of Health, Labor and Welfare as the standard.

Results

eGFR and prevalence of smoking were significantly lower in patients with mood disorder group than those with schizophrenia group by adjustment for age. In comparisons between patients with schizophrenia group or mood disorders group and each standard, the ratio of silent brain infarction (SBI) and cerebral infarction were significantly high in both groups. Schizophrenia group showed significantly higher prevalence of diabetes, low high-density lipoprotein (HDL) cholesterolemia, metabolic syndrome and smoking than the standard. Mood disorders group had significantly high prevalence of low HDL-cholesterolemia compared with the standard. Fasting blood glucose and HbA1c were significantly higher in schizophrenia group and female mood disorders group than the standard. Female mood disorders group had significantly decreased eGFR with increased ratio of eGFR < 60 ml/min than the standard.

Conclusions

Participants of both groups had increased ratio of SBI and cerebral infarction, accompanied with glucose and lipid disorders. Compared with schizophrenia group, mood disorders group showed significantly low eGFR and prevalence of smoking.

Background

It is well known that psychiatric patients have a short life expectancy. Henekens et al. [1] reported that schizophrenic patients have approximately 15 years shorter life time than general population and more than 60% of deaths are due to coronary heart diseases in the United States. In the countries from Europe, Asia, Australia, Africa and Japan predicted life time is 11–22 years shorter than the general population [2, 3]. Crump et al. [4] and Smith et al. [5] also reported that cardiovascular diseases and malignancy are the main causes of death in psychiatric patients, and cardiovascular diseases are likely to be underrecognized and undertreated in schizophrenic patients. These facts indicate that cardiovascular diseases are one of the most important causes of short life expectancy in psychiatric patients.

Diabetes, smoking, hypertension, dyslipidemia, visceral type obesity and chronic kidney disease (CKD) are risk factors of cardiovascular diseases. Indeed, there are many reports that schizophrenic patients have a high rate of diabetes, smoking, low HDL-cholesterolemia, obesity and metabolic syndrome [6,7,8]. Psychiatric patients tend to have unhealthy eating habits, shortage of exercise and smoking [8]. It is probable that these unhealthy lifestyles are related with increased risk factors of cardiovascular diseases. Furthermore, schizophrenic patients usually are administered typical or atypical antipsychotics. Halfdanarson et al. [9] reported that use of typical antipsychotics was decreased but that of atypical antipsychotics was elevated in the past 10 years globally. Some atypical antipsychotics cause adverse effects on glucose and lipid metabolism and induce diabetes and dyslipidemia [10, 11]. These side effects of antipsychotics also increase the risks of cardiovascular diseases.

Saku et al. [12] and Kondo et al. [3] reported that the standardized mortality rate of schizophrenic patients with heart disease was higher than in the general population in Japan, but they did not show that the precise classification of heart disease and other vascular diseases. Recently, our study has shown that psychiatric inpatients have increased silent brain infarction (SBI) and cerebral infarctions compared with Japanese healthy controls, accompanied with high prevalence of diabetes and low HDL-cholesterolemia [13]. These results suggest that cerebral incidents are also important in quality of life in psychiatric patients of Japan.

Psychiatric patients of our previous study were hospitalized patients who were diagnosed as schizophrenic group 69.1%, mood disorders group 18.4% and others 12.5% [13]. Schizophrenia and mood disorders are primary psychiatric diseases. Atypical antipsychotics are the major medication used to treat schizophrenia [9], and anti-depressants, mood-stabilizers and atypical antipsychotics are used to treat mood disorders. Therefore, it is possible that there are different metabolic changes in patients with schizophrenia and mood disorders. This is an essential point to plan the lowering the incidence of lifestyle-related diseases and cardiovascular diseases in each psychiatric patient with schizophrenia or mood disorders.

In this present study, we investigated the similarities and differences of lifestyle-related diseases between schizophrenia and mood disorders and also metabolic differences between patients with schizophrenia or mood disorders, and each standard in Japan. Decreased renal function is reported in hospitalized patients with female mood disorders.

Methods

Study design and study subjects

This cross-sectional observational study was performed from January 2015 to December 2017 at Kohnodai Hospital, National Center for Global Health and Medicine. Study participants were 189 Japanese hospitalized patients (82 males and 107 females) in the Psychiatry Department at Kohnodai Hospital. The diagnosis of psychiatric disorder was established as follows. Trained psychiatrists carried out neurological examinations and a diagnostic interview of the patients and reviewed information from the patients’ relatives. They excluded organic mental disorders and mental and behavioral disorders due to psychoactive substance use. A diagnosis was made using the ICD-10 classification of mental and behavioral disorders. Then, several psychiatrists discussed the assessment of the diagnosis and treatments in every patient at the conference opening every week. We then classified participants by schizophrenia group (F2 group, schizophrenia (F20), acute and transient psychotic disorders (F23) and schizoaffective disorders (F25)), mood disorders group (F3 group, bipolar affective disorder (F31), depressive episode (F32) and recurrent depressive disorder (F33)) and other mental disorders (Alzheimer’s disease, stimulant psychosis and somatoform disorders).

The study protocol was approved by the Ethics Committees of Chiba University (No. 182) and the National Center for Global Health and Medicine (No. 1837). All participants were provided with a written informed consent form, and explanation and participation agreement were performed in accordance with the Declaration of Helsinki principles.

Diagnosis of somatic diseases in study participants

The definition of hypertension was above 140 mmHg of systolic blood pressure and/or above 90 mmHg of diastolic blood pressure [14]. Diabetes mellitus was defined as HbA1c over 6.5% and fasting plasma glucose (FPG) over 126 mg/dl [15]. High LDL-cholesterolemia (fasting serum LDL-cholesterol (LDL-C) ≥ 140 mg/dl) or low HDL-cholesterolemia (fasting serum HDL-cholesterol (HDL-C) < 40 mg/dl) or hypertriglyceridemia (fasting serum triglyceride (TG) ≥ 150 mg/dl) were described as dyslipidemia [16]. Patients were also counted as hypertension, diabetes or dyslipidemia if they used anti-hypertensive (Ca antagonists, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics and β-blockers) or hypoglycemic (insulins, glucagon-like peptide-1 receptor agonists, biguanides, sulfonylureas, α-glucosidase inhibitors, thiazolidines, dipeptidyl peptidase-4 inhibitors and sodium glucose transporter-2 inhibitors) or anti-dyslipidemic drugs (statins, fibrates and ezetimibe), respectively. The diagnosis of metabolic syndrome (Met-S) was followed according to the definition of the Japan Society for the Study of Obesity. Met-S was diagnosed when waist circumference (male ≥ 85 cm, female ≥ 90 cm) plus two of the following criteria are met: high blood pressure (≥ 130/85), reduced HDL-C (< 40 mg/dl) and/or raised TG (≥ 150 mg/dl), and raised fasting hyperglycemia (≥ 110 mg/dl) [17]. Cerebral infarction was diagnosed by the presence of neurological symptoms and signs corresponding to brain imaging. The definition of smokers was patients who smoked until 1 month before admission.

Data collections

Information on patients’ demographic data and medical history were obtained from their medical records. Body mass index (BMI) was calculated by their height and weight. Waist circumference was measured at a level midway between the lowest rib and the iliac crest. Hospital staff measured blood pressure on the right arm of a patient before breakfast. Blood samples were obtained from patients after 12 h starvation. Total cholesterol (TC) and TG were assayed by enzymatic method and HDL-C was by direct method. LDL-C was calculated by Friedewald formula from TC, TG and HDL-C (TC-TG/5-HDL-C) and non-HDL cholesterol (non-HDL-C) was TC minus HDL-C. HbA1c was measured by the high performance liquid chromatography (HPLC) method, and fasting plasma glucose and creatinine were by enzymatic method. Estimated glomerular filtration rate (eGFR) was calculated by serum creatinine level, age and gender.

Brain imaging

The magnetic resonance imaging (MRI) examinations were performed in 5 mm thickness with 2 mm slice gap using a 1.5 Tesla MRI system (Siemens Magnetom Symphony). Patients underwent T1- and T2-weighted MRI and fluid-attenuated inversion recovery (FLAIR) of the brain as described by Yoshida et al. [18]. FLAIR images were used to distinguish infarcts from dilated perivascular spaces. We diagnosed silent brain infarction (SBI) as follows: (1) spotty area ≥ 3 mm in diameter showing high density in T2 and FLAIR images and low density in T1 image, (2) lack of neurological signs explained by MRI lesions, (3) no medical history of clinical symptoms of stroke [19]. 790 elderly volunteers (330 females and 460 males, mean age 61.0 years old, range 40–88) were used as control of SBI [20]. All of 790 volunteers were living independently at home without apparent history of stroke or dementia.

Statistical analysis

When we compared physical and metabolic differences between F2 group and F3 group, first we used t-test in quantitative variables and Fisher’s exact test in qualitative variables without any adjustments. Next, we estimated age-adjusted mean differences and Odds ratios between F2 and F3 groups, using analysis of covariance (ANCOVA) and logistic regression analysis, respectively. Quantitative variables were BMI, waist circumstance, systolic blood pressure, diastolic blood pressure, LDL-C, HDL-C, triglyceride, non-HDL-C, fasting blood glucose, HbA1c, serum creatinine and eGFR. Qualitative variables were prevalence of hypertension, diabetes mellitus, high LDL-cholesterolemia, low HDL-cholesterolemia, hypertriglyceridemia, metabolic syndrome, smoking, and ratios of SBI and cerebral infarction, eGFR < 60 ml/min and albuminuria.

In comparisons between patients with schizophrenia or mood disorders and each standard, we quoted ‘The National Health and Nutrition Survey in Japan 2015’ produced by the Japanese Ministry of Health, Labor and Welfare [21] as the healthy Japanese standard. This survey was performed in 6655 persons (3064 were male, 3591 were female) chosen at random from all districts of Japan at November in 2015. Age of target persons was distributed from 1 to over 70 years old. For albuminuria, the data of the Takahata study was used [22].

Means or ratios in the standard group were calculated by adjusting sex and age configuration to patient group. Next, we estimated means or ratios with 95% of confidence intervals (CIs) of the patient group. Then we compared characteristics of F2 group or F3 group with those of each standard group. All analyses were conducted using a statistical software (SAS Analytics Pro Academic Suite; SAS Institute Inc.)

Results

Profile of study participants

Table 1 shows the profile of study patients. Schizophrenia group (F2 group) were 144 persons, and mood disorders group (F3 group) were 45. The ratio of male to female was 1:1.32 (62 persons: 82 persons) in F2 group, and was 1:1.25 (20 persons: 25 persons) in F3 group, indicating a similar ratio of male to female in both groups. The average age was approximately 13 years older in F3 group than in F2 group.

Table 1 Profile of study participants
Full size table

Comparisons of physical characteristics and disorders between study participants of F2 group and F3 group

First, we compared physical characteristics and disorders between F2 and F3 study participants directly (Table 2). Significant difference between F2 and F3 groups was only observed in the prevalence of smoking by adjustment with age (p = 0.0148). Age-adjusted analysis showed no significant differences of BMI, blood pressure, the prevalence of hypertension and high LDL-cholesterolemia, and the ratio of SBI and cerebral infarction, in spite of their differences by simple analysis without age-adjustment.

Table 2 Comparisons of physical characteristics and disorders between F2 and F3 study participants
Full size table

Table 3 shows that female BMI was significantly higher in the F2 group compared with the age-adjusted Japanese standard population (the standard) but was lower in the male F3 group. Waist circumference and blood pressure were not significantly different in either group except lower diastolic blood pressure of male F3 group. We calculated the prevalence of hypertension, diabetes mellitus, dyslipidemia, metabolic syndrome and smoking in both study groups (Table 3). The ratio of low HDL-cholesterolemia was significantly higher in both groups than the standard. The ratio of diabetes was significantly high in the F2 group but was no significant difference in the F3 group compared with the standard. These results are in accordance with the increased ratio of metabolic syndrome in the F2 group. However, the ratios of high LDL-cholesterolemia and hypertension showed no significant differences in both groups compared with the standard except lower ratio of hypertension in female F2 group, and the ratio of hypertriglyceridemia was significantly lower in both male groups. The prevalence of smoking was significantly higher in the F2 group than the standard (Table 3).

Table 3 Differences of physical characteristics and disorders between F2 and F3 study participants and standard
Full size table

As far as brain MRI, 185 patients agreed to undergo brain imaging. 2 and 3 patients were diagnosed as cerebral infarction in F2 and F3 groups, respectively, by the presence of neurological symptoms and signs inferred from brain imaging. The ratios of SBI plus cerebral infarction were 0.234 and 0.477 in the F2 and F3 groups, respectively, and significantly higher than the age-adjusted ratio of each control (Table 3).

Comparisons of metabolic characteristics between study participants of F2 group and F3 group

Tables 4 and 5 show serum blood levels of lipid and glucose, and renal function. First, we compared metabolic characteristics between F2 and F3 study participants directly (Table 4). Female eGFR in F3 group was significantly lower than female F2 group by age-adjustment (p = 0.0225). Age-adjusted analysis showed no significant differences of HbA1c, serum creatinine and the ratio of eGFR < 60 ml/min, in spite of their differences by simple analysis without age-adjustment.

Table 4 Comparisons of metabolic characteristics between F2 and F3 study participants
Full size table
Table 5 Differences of metabolic characteristics between F2 or F3 study participants and standard
Full size table

Patients in the F2 group had significantly lower levels of HDL-C and TG than the standard except TG in the females. In F3 group, TG in males was significantly low but TG in females and HDL-C were not significantly different from the standard. LDL-C levels were not significantly different in either group compared with the standard. Non-HDL-C level was significantly low in male F2 and F3 groups. FPG and HbA1c were significantly higher in the F2 group and female F3 group than the standard.

Chronic kidney disease (CKD) is recognized as one of the important risk factors of cardiovascular diseases. The definition of CKD is continuous decreased GFR (GFR < 60 ml/min) and/or albuminuria [23]. The mean level of eGFR was 68.7 ml/min (95% CI was 61.4–76.1) in female F3 group and significantly lower than the age-adjusted mean of the standard (77.5 ml/min) (Table 5). We also calculated the ratio of eGFR lower than 60 ml/min. The ratio of eGFR lower than 60 ml/min was significantly higher in the female F3 group than the female standard, suggesting increased CKD. We also checked the urine albumin in subjects over 40 years old, another criterion of CKD definition [23]. The ratio of albuminuria tended to higher in the female F3 group than the female standard.

eGFR levels were not significantly different in the F2 group and male F3 group compared with each standard group (Table 5).

Psychiatric medications administered to study participants

In the F2 group, 76.6% of the psychiatric medications used is atypical antipsychotics, 21.4% is typical and 1.9% is other psychotropic medications. Among administered medicines in the F3 group, atypical antipsychotics accounted for 54.7%, antidepressants and mood stabilizers 34.0% and typical antipsychotics 9.4% (Additional file 1). Therefore, most of the schizophrenic patients were treated with antipsychotics, but mood disorders patients were treated with various psychotropic medications containing atypical antipsychotics, antidepressants and mood stabilizers.

Discussion

The present study shows that silent brain infarction and cerebral infarction were increased in patients with both schizophrenia and mood disorders, accompanied by glucose and lipid disorders. Differences between inpatients with schizophrenia and those with mood disorders were observed in renal function and prevalence of smoking.

Low HDL-cholesterolemia is defined by a serum level below 40 mg/dl [16]. We observed low HDL-cholesterolemia in this study. There are many reports that HDL-C level is low in medicated schizophrenia [24, 25]. Sagud et al. [26] reported that HDL-C was decreased in patients with bipolar affective disorder and major depressive disorder, but Peng et al. [27] showed that serum HDL-C level was elevated in those with major depressive disorder excluding psychiatric medications. HDL-C levels are decided by not only lifestyle-related diseases, but using psychotropic medications. Antipsychotics are known to lower serum HDL-C levels [24, 25]. It is reported that antidepressants are associated with weight gain but have fewer effects on lipid and glucose metabolism [28, 29]. Usually, patients with schizophrenia use atypical or typical antipsychotics, but those with mood disorders are administered by not only antidepressants or mood stabilizers but atypical antipsychotics. Therefore, it is possible to think that drug variation is one of the reasons why HDL-C in mood disorders is different in these reports.

Levels of serum TG and non-HDL-C were significantly low compared with the standard in both male F2 and F3 groups, and LDL-C was almost the same as the standard in both groups. Kingsbury et al. [30] described lower levels of serum TG in ziprasidone-treated patients with schizophrenia. However, there were reports of high serum TG or LDL-C levels in schizophrenic patients [24, 31]. Furthermore, Sugai et al. [32] showed that the levels of TG and LDL-C were higher in outpatients with schizophrenia than in inpatients. In patients with mood disorders, serum lipid levels are also variable. Hummel et al. [33] reported that serum TG level was higher and LDL-C was lower than controls. Lehto et al. [34] showed that serum TG and LDL-C were increased compared with controls. There was also a report that serum LDL-C was not changed in mood disorders patients [35]. These differences of TG and LDL-C levels might be dependent on the situation of the patients such as outpatients or inpatients, and drugs administered.

It is reported that the increased ratio of diabetes and high FPG are observed in patients with both schizophrenia and mood disorders, in accordance with high FPG and HbA1c in patients of the F2 group and female F3 group in our study. Stubbs et al. [36] described that schizophrenic patients had at least double the risk of diabetes by meta-analysis. Newcomer [37], Wysokinski et al. [38] and Vancampfort et al. [39] showed that the prevalence of diabetes or the level of FPG was high in patients with schizophrenia and those with mood disorders. It is well known that poor lifestyle is one of the major causes of increased diabetes. There are also many reports that antipsychotics, especially atypical ones have side effects on glucose metabolism [10, 40]. Furthermore, Ji et al. [41] also reported the genetic overlap between type 2 diabetes and major depressive disorders. Causes of increased diabetes or FPG in patients with schizophrenia and mood disorders remain to be elucidated.

There are several reports concerning psychiatric disorders and renal function. Tzeng et al. [42] reported that schizophrenia is associated with a 25% increase in the risk of developing CKD for 3 years follow up period. There are other reports that the prevalence of CKD is not different between schizophrenic patients and control [4], and the incidence of end-stage renal disease is low in schizophrenic patients [43]. Rej [44] and Kessing [45] showed that Lithium, mood stabilizing treatment for bipolar disorder, had an effect on renal function and induced CKD. This F3 group contained 8% Lithium users. eGFR in the female F3 group excluding Lithium users was 67.2 ml/min and the standard was 77.2 ml/min, which was significantly different, indicating that Lithium is not correlated with CKD in the F3 group in our study. We need to have an extended follow up renal function in these F2 and F3 patients.

As risk factors of developing CKD, there are lifestyle-related diseases, e.g., hypertension, diabetes, dyslipidemia, obesity and smoking [46]. Table 4 shows that eGFR was significantly lower in F3 group than F2 group by adjustment for age (p = 0.0139). By adjustments for age and prevalence of hypertension, there was significant difference between F2 group and F3 group (p = 0.0232). However, we have no significant differences by adjustment for smoking and diabetes (p = 0.2093 and p = 0.6309, respectively). These results mean that there is significant difference of eGFR between F2 and F3 groups which cannot be explained by age and hypertension. The causes of lowering eGFR in mood disorders remain to be clarified.

The ratios of SBI and cerebral infarction were higher in both F2 and F3 groups, compared with each control [20], indicating the increasing tendency to cerebrovascular changes. We did not detect significant differences between F2 and F3 groups by age-adjustment. There are reports about the relation of cerebrovascular changes to major depression. Yanai et al. [47] reported that patients with depression and SBI were more likely to develop psychiatric and neurological disorders than those with depression without SBI. A 10 years follow-up study showed that the presence of SBI is associated with a relatively poor prognosis in patients with depression [48]. The term ‘vascular depression’ has been used to describe depression occurring later in life and characterized by cerebral changes related to depression onset. The mean age of the F3 group is 62.6 years old. Therefore, a part of SBI positive depressive patients might be vascular depression.

This study also has some limitations. First, it was a cross-sectional study. It is impossible to clarify the cause-effect relationship between diabetes, hypertension, lipid, eGFR and SBI. Second, patients in our study were inpatients. It is probable that lifestyle-related diseases and metabolic profiles are not same in inpatients and outpatients [49]. Third, the number of mood disorders group is 45, about one-third of schizophrenia group. It may cause to miss the significant difference which can be detected if patient numbers are same in both groups. Fourth, the number of mood disorders group is small and much different from schizophrenic group to analyze the characteristics of bipolar affective disorder and major depressive disorder, separately.

Conclusions

In conclusion, we found that patients with schizophrenia or mood disorders had increased ratio of SBI and cerebral infarction accompanied with glucose and lipid disorders in this study. Patients with mood disorders had decreased eGFR and prevalence of smoking compared with those with schizophrenia.

Availability of data and materials

Not applicable.

Abbreviations

ANCOVA:

Analysis of covariance

BMI:

Body mass index

CI:

Confidence interval

CKD:

Chronic kidney disease

eGFR:

Estimated glomerular filtration rate

FLAIR:

Fluid-attenuated inversion recovery

FPG:

Fasting plasma glucose

HDL:

High-density lipoprotein

HPLC:

High performance liquid chromatography

LDL:

Low-density lipoprotein

MRI:

The magnetic resonance imaging

N.A.:

Not applicable

N.S.:

Not significant

SBI:

Silent brain infarction

TC:

Total cholesterol

TG:

Triglyceride

References

  1. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115–21.

    PubMed  Google Scholar 

  2. Hjorthoj C, Sturup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4:295–301.

    PubMed  Google Scholar 

  3. Kondo S, Kumakura Y, Kanehata A, et al. Premature deaths among individuals with severe mental illness after discharge form long-term hospitalisation in Japan: a naturalistic observation during a 24-year period. BJPsych open. 2017;3:193–5.

    PubMed  PubMed Central  Google Scholar 

  4. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish National Cohort Study. Am J Psychiatry. 2013;170:324–33.

    PubMed  Google Scholar 

  5. Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open. 2013;3:e2808.

    Google Scholar 

  6. Okumura Y, Ito H, Kobayashi M, et al. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophrenia Res. 2010;119:145–52.

    Google Scholar 

  7. Sugawara N, Yasui-Furukori N, Sato Y, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophrenia Res. 2010;123:244–50.

    Google Scholar 

  8. Davidson S, Judd F, Jolley D, et al. Cardiovascular risk factors for people with mental illness. Aust NZJ Psychiatry. 2001;35:196–202.

    CAS  Google Scholar 

  9. Halfdanarson O, Zoega H, Aagaard L, et al. International trends in anti-psychotic use: a study in 16 contries, 2005-2014. Eur Neuropsychopharmacol. 2017;27:1064–76.

    CAS  PubMed  Google Scholar 

  10. Newcomer JW, Rantner RE, Eriksson JW, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychitry. 2009;70:487–99.

    CAS  Google Scholar 

  11. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Res. 2004;70:1–17.

    Google Scholar 

  12. Saku M, Tokudome S, Ikeda M, et al. Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia. Int J Epidemiol. 1995;24:366–72.

    CAS  PubMed  Google Scholar 

  13. Kanzaki T, Uju Y, Sekine K, et al. Increased silent brain infarction accompanied with high prevalence of diabetes and dyslipidemia in psychiatric inpatients: a cross-sectional study. Prim Care Companion CNS Disord. 2015;17:115–21.

    Google Scholar 

  14. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2014). Hypertens Res. 2014;37:253–390.

    Google Scholar 

  15. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T. The committee of the Japan Diabetic Society on the diagnostic criteria of diabetes mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int. 2010;1:2–20.

    Google Scholar 

  16. Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for dyslipidemia. J Atheroscler Thromb. 2013;20:655–60.

    Google Scholar 

  17. Matuzawa Y. Metabolic syndrome-definition and diagnostic criteria in Japan. J Atheroscler Thromb. 2005;12:301.

    Google Scholar 

  18. Yoshida M, Tomitori H, Machi Y, et al. Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis. 2009;203:557–62.

    CAS  PubMed  Google Scholar 

  19. Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34:1126–9.

    PubMed  Google Scholar 

  20. Yoshida M, Higashi K, Kobayashi E, et al. Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. Atherosclerosis. 2010;211:475–9.

    CAS  PubMed  Google Scholar 

  21. Ministry of Health, Labor and Welfare, Japan. The National Health and Nutrition Survey in Japan. 2015.

  22. Konta T, Hao Z, Abiko H, et al. Prevalence and risk factor analysis of microalbuinuria in Japanese general population: the Takahata study. Kidney Int. 2006;70:751–6.

    CAS  PubMed  Google Scholar 

  23. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089–100.

    PubMed  Google Scholar 

  24. Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci. 2007;61:54–8.

    CAS  PubMed  Google Scholar 

  25. Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis. 1984;51:163–9.

    CAS  PubMed  Google Scholar 

  26. Sagud M, Mihaljevic-Peles A, Pivac N, et al. Lipid levels in female patients with affective disorders. Psychiatry Res. 2009;168:218–21.

    CAS  PubMed  Google Scholar 

  27. Peng Y-F, Xiang Y, Wei Y-S. The significance of routine biochemical markers in patients with major depressive disorder. Sci Rep. 2016;6:34402.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets. 2015;15:252–60.

    CAS  PubMed  Google Scholar 

  29. Hennings JM, Schaaf L, Fulda S. Glucose metabolism and antidepressant medication. Curr Pharm Des. 2012;18:5900–19.

    CAS  PubMed  Google Scholar 

  30. Kingsbury SJ, Fayek M, Trufasiu D, et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry. 2001;62:347–9.

    CAS  PubMed  Google Scholar 

  31. Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second generation antipsychotics of body weight and metabolism- risk assessment and results from a prospective study. Pharmacopsychiatry. 2009;42:29–34.

    CAS  PubMed  Google Scholar 

  32. Sugai T, Suzuki Y, Yamazaki M, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS ONE. 2016;11:e166429.

    Google Scholar 

  33. Hummel J, Westphal S, Weber-Hamann B, et al. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. J Clin Psychiatry. 2011;72:885–91.

    CAS  PubMed  Google Scholar 

  34. Lehto SM, Niskanen L, Tolmunen T, et al. Low serum HDL-cholesterol levels are associated with long symptom duration in patients with major depressive disorder. Psychiatry Clin Neurosci. 2010;64:279–83.

    CAS  PubMed  Google Scholar 

  35. Nunes SOV, de Melo LGP, de Castro MRP, et al. Atherogenic index of plasma and atherognic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J Affect Disord. 2015;172:55–62.

    CAS  PubMed  Google Scholar 

  36. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015;132:144–57.

    CAS  PubMed  Google Scholar 

  37. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67(67 supple):25–30.

    CAS  PubMed  Google Scholar 

  38. Wysokinski A, Strzelecki D, Kloszewska I. Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. Diabetes Metab Syndr. 2015;9:168–76.

    PubMed  Google Scholar 

  39. Vancampfort D, Mitchell AJ, De Hert M, et al. Type 2 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and predictors. Depress Anxiety. 2015;32:763–73.

    PubMed  Google Scholar 

  40. Akhtar S, Kelly C, Gallagher A, Petrie JR. Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk. Br J Diabetes Vasc Dis. 2004;4:303–9.

    CAS  Google Scholar 

  41. Ji H-F, Zhuang Q-S, Shen L. Genetic overlap between type 2 diabetes and major depressive disorder identified by bioinformatics analysis. Oncotarget. 2016;7:17410–4.

    PubMed  PubMed Central  Google Scholar 

  42. Tzeng N-S, Hsu Y-H, Ho S-Y, et al. Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study. BMJ Open. 2015;5:e6777.

    Google Scholar 

  43. Hsu Y-H, Cheng J-S, Ouyang W-C, et al. Lower incidence of end-stage renal disease but suboptimal pre-dialysis renal care in schizophrenia: a 14-year nationwide cohort study. PLoS ONE. 2015;10:e140510.

    Google Scholar 

  44. Rej S, Elie D, Mucsi I, Looper KJ, Segal M. Chronic kidney disease in Lithium-treated older adults: a review of epidemiology, mechanisms, and implications for the treatment of late-life mood disorders. Drugs Aging. 2015;32:31–42.

    CAS  PubMed  Google Scholar 

  45. Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Use of lithium and anticonvulsants and the rate of chronic kidney disease. A nationwide population-based study. JAMA Psychiatry. 2015;72:1182–91.

    PubMed  Google Scholar 

  46. Yamagata K, Ishida K, Sairenchi T, et al. Risk factor for chronic kidney diseases in a community-based population: 10-year follow-up study. Kidney Int. 2007;71:159–66.

    CAS  PubMed  Google Scholar 

  47. Yanai I, Fujikawa T, Horiguchi J, et al. The 3-year course and outcome of patients with major depression and silent cerebral infarction. J Affect Disord. 1998;47:25–30.

    CAS  PubMed  Google Scholar 

  48. Yamashita H, Fujikawa T, Takami H, et al. Long-term prognosis of patients with major depression and silent cerebral infarction. Neuropsychobiology. 2010;62:177–81.

    CAS  PubMed  Google Scholar 

  49. Uju Y, Kanzaki T, Yamasaki Y, et al. Metabolic changes of Japanese schizophrenic patients transferred from hospitalization to outpatients. Global Health Med. 2020;2:178–83.

    Google Scholar 

Download references

Acknowledgements

We thank Dr. Yuichi Sugaya (Department of Neurosurgery, Asahi Hospital, Asahi city, Chiba, Japan) for help in diagnosing SBI by brain MRI.

Funding

This study was supported by Grants from the Chiba Foundation for Health Promotion & Disease Prevention (Chiba, Japan) to Tetsuto Kanzaki (No. II-2, 2016). The funder had no role in the design of the study and collection, analysis and interpretation of data, and in the decision to publish and the preparation of the manuscript.

Author information

Author notes

  1. Yoriyasu Uju and Tetsuto Kanzaki contributed equally to this work

Authors and Affiliations

  1. Department of Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Japan

    Yoriyasu Uju, Tadayuki Kondo, Hideki Nanasawa, Yu Takeuchi, Yuta Yanagisawa, Shun Kusanishi, Chieko Nakano, Tetsuro Enomoto & Tatsuro Hayakawa

  2. Department of Drug Informatics, Graduate School and Faculty of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, Japan

    Tetsuto Kanzaki & Yuki Yamasaki

  3. Department of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Japan

    Akahito Sako & Hidekazu Yanai

  4. Department of Diabetes, Endocrinology and Metabolism, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Japan

    Shunichi Mishima

  5. Department of Clinical Medicine, Faculty of Pharmacy, Chiba Institute of Science, 15-8, Shiomi-cho, Choshi, Japan

    Seisuke Mimori

  6. Amine Pharma Research Institute, Innovation Plaza at Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, Japan

    Kazuei Igarashi

  7. Department of Biostatistics, Faculty of Pharmacy, Chiba Institute of Science, 15-8, Shiomi-cho, Choshi, Japan

    Tsuyoshi Takizawa

Authors
  1. Yoriyasu Uju
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuto Kanzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuki Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tadayuki Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideki Nanasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuta Yanagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shun Kusanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chieko Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tetsuro Enomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Akahito Sako
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hidekazu Yanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shunichi Mishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Seisuke Mimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kazuei Igarashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Tsuyoshi Takizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Tatsuro Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TKa and YU designed this study and major contributors in writing the manuscript. TKo, HN, YT, YYan, SK, CN, TE and SMis collected samples and obtained patients’ informed consent. YYam, AS, HY, SMim, KI, TT and TH contributed to data collection, analysis and interpretation. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Tetsuto Kanzaki.

Ethics declarations

Ethics approval and consent to participate

This study protocol was approved by the Ethics Committees of Chiba University (No. 182) and the National Center for Global Health and Medicine (No. 1837). All participants were provided with a written informed consent form, and explanation and participation agreement were performed in accordance with the Declaration of Helsinki principles.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uju, Y., Kanzaki, T., Yamasaki, Y. et al. A cross-sectional study on metabolic similarities and differences between inpatients with schizophrenia and those with mood disorders. Ann Gen Psychiatry 19, 53 (2020). https://doi.org/10.1186/s12991-020-00303-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12991-020-00303-5

Keywords

Annals of General Psychiatry

ISSN: 1744-859X